Clinical trials: Psoriatic Subjects
Psoriatic Arthritis
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis who have not been previously treated with DMARDs.
- Trial name
- PALACE4 (NCT01307423)
- Testing
- Apremilast 20mg, Apremilast 30mg
- Where
- 118 sites in United States, Australia and 16 more
- Volunteers
- 529 people
- Sponsor
- Amgen
Arthritis, Psoriatic
A Study of the Safety and Efficacy of Golimumab in Patients With Active Psoriatic Arthritis
The purpose of this study is to evaluate the safety and efficacy (improvement of signs and symptoms) of subcutaneous (under the skin) injections of golimumab for the treatment of active psoriatic arthritis (PsA).
- Trial name
- GO-REVEAL (NCT00265096)
- Testing
- golimumab
- Where
- 51 sites in United States, Belgium and 4 more
- Volunteers
- 407 people
- Sponsor
- Centocor, Inc.
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
This is a study to compare the efficacy of bimekizumab versus placebo and an active comparator in the treatment of subjects with moderate to severe chronic plaque psoriasis (PSO).
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE VIVID (NCT03370133)
- Testing
- Bimekizumab, Ustekinumab
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 567 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
This study is designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in participants with active Psoriatic Arthritis (PsA).
- Trial name
- NCT05153148
- Testing
- NDI-034858
- Where
- 56 sites in United States, Czechia and 2 more
- Volunteers
- 305 people
- Sponsor
- Takeda
Active Psoriatic Arthritis
Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)
The main purpose of study is to assess the dose-response relationship of BMS-986165 (Dose A or Dose B once daily [QD]) at Week 16 in the treatment of participants with active PsA.
- Trial name
- NCT03881059
- Testing
- BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab
- Where
- 94 sites in United States, Czechia and 7 more
- Volunteers
- 203 people
- Sponsor
- Bristol-Myers Squibb
Psoriatic Arthritis
AMG 827 in Subjects With Psoriatic Arthritis
The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis
- Trial name
- NCT01516957
- Testing
- AMG 827 140, AMG 827 280, AMG 827 210
- Where
- 31 sites in United States, Canada
- Volunteers
- 168 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriatic Arthritis
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
- Trial name
- NCT01925768
- Testing
- Apremilast 30 mg
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 219 people
- Sponsor
- Amgen
Psoriatic Arthritis
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
The purpose of this study is to provide 24 - 52 week efficacy, safety and tolerability data, and up to 3-year efficacy, safety and tolerability data in subjects with active Psoriatic Arthritis despite current or previous…
- Trial name
- NCT01989468
- Testing
- Secukinumab
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 414 people
- Sponsor
- Novartis Pharmaceuticals
Arthritis, Psoriatic
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
This study is undertaken to compare the efficacy and onset of action of infliximab plus methotrexate (IFX + MTX) versus methotrexate alone (MTX) in methotrexate naïve active psoriatic arthritis patients.
- Trial name
- NCT00367237
- Testing
- Infliximab + methotrexate (IFX + MTX), Methotrexate (MTX)
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
Psoriasis, Psoriatic Arthritis
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
This study will test the clinical effectiveness and safety of two orally administered doses of apremilast compared to placebo in Japanese patients with moderate-to-severe plaque-type psoriasis.
- Conditions
- Psoriasis, Psoriatic Arthritis, Psoriasis Arthropatica
- Trial name
- NCT01988103
- Testing
- Apremilast
- Where
- 56 sites in Japan
- Volunteers
- 254 people
- Sponsor
- Amgen
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (Enbrel®).
- Trial name
- NCT01901185
- Testing
- Etanercept / Autoinjector A
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Amgen
Arthritis, Psoriatic
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration.
- Trial name
- FOREMOST (NCT03747939)
- Testing
- Apremilast (CC-10004)
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 310 people
- Sponsor
- Amgen
Psoriatic Arthritis
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy
The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis…
- Trial name
- PENGUIN 2 (NCT04115839)
- Testing
- Filgotinib
- Where
- 59 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- Gilead Sciences
Psoriatic Arthritis
A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)
An interventional Phase 4 open-label, randomized, controlled, parallel-group, multi-country study in participants with psoriatic arthritis (PsA) consisting of 2 parts: Part 1 (Day 1 up to Week 16) is designed to compare the…
- Trial name
- CONTROL (NCT02814175)
- Testing
- methotrexate (MTX), adalimumab (ADA)
- Where
- 60 sites in United States, Australia and 12 more
- Volunteers
- 246 people
- Sponsor
- AbbVie
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE READY (NCT03410992)
- Testing
- Bimekizumab
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 435 people
- Sponsor
- UCB Biopharma SRL
Psoriatic Arthritis
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis
The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in adults with psoriatic arthritis.
- Trial name
- NCT02376790
- Testing
- Etanercept, Methotrexate
- Where
- 138 sites in United States, Argentina and 16 more
- Volunteers
- 851 people
- Sponsor
- Amgen
Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis
Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease
The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and…
- Conditions
- Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Moderately to Severely Active Crohn's Disease
- Trial name
- NCT03357471
- Testing
- e-Device
- Where
- 22 sites in United States
- Volunteers
- 70 people
- Sponsor
- UCB Biopharma S.P.R.L.
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of this study was to determine if secukinumab is effective and safe in the treatment of plaque type psoriasis
- Trial name
- NCT03066609
- Testing
- Secukinumab 150 mg s.c., Secukinumab 300 mg s.c.
- Where
- 32 sites in China, Hungary and 4 more
- Volunteers
- 543 people
- Sponsor
- Novartis Pharmaceuticals
Psoriatic Arthritis
Phase II Study of Apremilast (CC-10004) in Adults With in Psoriatic Arthritis
This study is to look at the preliminary efficacy and safety of 2 dose regimens of apremilast (20 mg twice a day and 40 mg once a day) versus placebo in patients with active psoriatic arthritis.
- Trial name
- NCT00456092
- Testing
- Apremilast
- Where
- 38 sites in Belgium, Canada and 3 more
- Volunteers
- 204 people
- Sponsor
- Amgen
Psoriatic Arthritis
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
- Trial name
- AMVISION-1 (NCT02029495)
- Testing
- 210 mg brodalumab, 140 mg brodalumab
- Where
- 152 sites in United States, Belgium and 15 more
- Volunteers
- 478 people
- Sponsor
- Bausch Health Americas, Inc.